File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Event-Free Survival by Residual Cancer Burden with Pembrolizumab in Early-Stage TNBC: Exploratory Analysis from KEYNOTE-522

TitleEvent-Free Survival by Residual Cancer Burden with Pembrolizumab in Early-Stage TNBC: Exploratory Analysis from KEYNOTE-522
Authors
Issue Date16-Feb-2024
PublisherElsevier
Citation
Annals of Oncology, 2024 How to Cite?
Persistent Identifierhttp://hdl.handle.net/10722/340096
ISSN
2023 Impact Factor: 56.7
2023 SCImago Journal Rankings: 13.942

 

DC FieldValueLanguage
dc.contributor.authorPusztai, L-
dc.contributor.authorDenkert, C-
dc.contributor.authorO’Shaughnessy, J-
dc.contributor.authorCortes, J-
dc.contributor.authorDent, R-
dc.contributor.authorMcArthur, H-
dc.contributor.authorKummel, S-
dc.contributor.authorBergh, J-
dc.contributor.authorPark, YH-
dc.contributor.authorHui, R-
dc.contributor.authorHarbeck, N-
dc.contributor.authorTakahashi, M-
dc.contributor.authorUntch, M-
dc.contributor.authorFasching, PA-
dc.contributor.authorCardoso, F-
dc.contributor.authorZhu, Y-
dc.contributor.authorPan, W-
dc.contributor.authorTryfonidis, K-
dc.contributor.authorSchmid, P-
dc.date.accessioned2024-03-11T10:41:38Z-
dc.date.available2024-03-11T10:41:38Z-
dc.date.issued2024-02-16-
dc.identifier.citationAnnals of Oncology, 2024-
dc.identifier.issn0923-7534-
dc.identifier.urihttp://hdl.handle.net/10722/340096-
dc.languageeng-
dc.publisherElsevier-
dc.relation.ispartofAnnals of Oncology-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.titleEvent-Free Survival by Residual Cancer Burden with Pembrolizumab in Early-Stage TNBC: Exploratory Analysis from KEYNOTE-522-
dc.typeArticle-
dc.identifier.doi10.1016/j.annonc.2024.02.002-
dc.identifier.eissn1569-8041-
dc.identifier.issnl0923-7534-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats